Such sPLA2-interaction inhibitors could be proposed as alternatives to the bisphosphonates (Center et al., 2020; D'Oronzo et al., 2021), the actual treatment of choice for several osteoclast disorders, since bisphosphonates are contraindicated in older patients with kidney impairment or cardiac disease (Dos Santos Ferreira et al., 2017; Rogers et al., 2020; de Roij van Zuijdewijn et al., 2021). The gene discussed is PLA2G10; the disease is heart disorder.